¼¼°èÀÇ ±¹¼Ò ºÐÀý »ç±¸Ã¼ °æÈ­Áõ(FSGS) Ä¡·áÁ¦ ½ÃÀå(2024-2031³â)
Global Focal Segmental Glomerulosclerosis Drugs Market - 2024-2031
»óǰÄÚµå : 1496888
¸®¼­Ä¡»ç : DataM Intelligence
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 181 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,350 £Ü 5,990,000
PDF & Excel (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,850 £Ü 6,679,000
PDF & Excel (Multiple User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,850 £Ü 10,811,000
PDF & Excel (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°³¿ä

¼¼°è ±¹¼Ò ºÐÀý »ç±¸Ã¼ °æÈ­Áõ(FSGS) Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 7¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. 2031³â¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2031³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 7.5%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù..

Ãʹ߼º ±¹¼Ò ºÐÀý »ç±¸Ã¼ °æÈ­Áõ(FSGS)Àº »ç±¸Ã¼¶ó´Â ½ÅÀåÀÇ ÀÛÀº ¿©°ú ´ÜÀ§¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½ÅÀå ÁúȯÀÇ ÀÏÁ¾À¸·Î, ½ÅÀå ÈäÅÍÈ­¸¦ µ¿¹ÝÇÕ´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ, À¯ÀüÀû ¿äÀÎ, ´Ù¸¥ ½Åü ºÎÀ§ °¨¿°, °æÈ­¼º Áúȯ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù.

»ç±¸Ã¼ ¼Õ»ó ¹× °ø°ÝÀ¸·Î ½ÅÀå ±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Èñ±ÍÁúȯ Áß ÇϳªÀÔ´Ï´Ù. ½ÅÀå °áÇÔÀº º¸Åë ºñ¸¸, °â»ó ÀûÇ÷±¸ ºóÇ÷, Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ, Ãâ»ê, HIV µî ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼ºÀå ÃËÁø¿äÀÎ

±¹¼Ò ºÐÀý »ç±¸Ã¼ °æÈ­Áõ(FSGS) Ä¡·áÁ¦(FSGS) ºÎ´ã Áõ°¡

Àü ¼¼°è ±¹¼Ò ºÐÀý »ç±¸Ã¼ °æÈ­Áõ(FSGS) Ä¡·áÁ¦ ½ÃÀå ¼ö¿ä´Â ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â FSGSÀÇ ºÎ´ã Áõ°¡ÀÔ´Ï´Ù. FSGS´Â Ç÷¾×¿¡¼­ ³ëÆó¹°À» °É·¯³»´Â ½ÅÀåÀÇ ÀÛÀº ºÎºÐÀÎ »ç±¸Ã¼¿¡ ÈäÅÍ Á¶Á÷ÀÌ »ý±â´Â ÁúȯÀÔ´Ï´Ù.

FSGS´Â ´Ù¾çÇÑ Áúº´¿¡ ÀÇÇØ ¹ß»ýÇϸç, FSGS´Â ½ÅºÎÀüÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ½É°¢ÇÑ Áúº´À¸·Î Åõ¼®À̳ª ½ÅÀå À̽ÄÀ¸·Î¸¸ Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù.

2023³â 8¿ù NCBI ¿¬±¸ ¹ßÇ¥¿¡ µû¸£¸é, ±¹¼Ò ±¹¼Ò ºÐÀý »ç±¸Ã¼ °æÈ­Áõ(FSGS)(FSGS)Àº ½ÅÁõÈıºÀÇ ¿øÀÎÀ¸·Î ÀÚÁÖ ¹ß»ýÇÏ´Â ÁúȯÀ¸·Î ¼ºÀÎÀÇ 40%, ¼Ò¾ÆÀÇ 20%¸¦ Â÷ÁöÇÕ´Ï´Ù.

¶ÇÇÑ, »õ·Î¿î Ä¡·á¹ý °³¹ß¿¡ ´ëÇÑ ³ôÀº °ü½Éµµ ¿¹Ãø ±â°£ µ¿¾È ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 2¿ù, ½ºÆÛ¼¾Æ¾(Sparsentan)À̶ó´Â ¾à¹°ÀÌ ±Þ¼ÓÇÑ Áúº´ ÁøÇà À§ÇèÀÌ ÀÖ´Â ¿ø¹ß¼º ¸é¿ª±Û·ÎºÒ¸° A ½ÅÁõ(IgAN) ȯÀÚÀÇ Ä¡·áÁ¦·Î FDAÀÇ Á¶±â ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù.

IgAN»Ó¸¸ ¾Æ´Ï¶ó, TraveleÀº ¶ÇÇÑ ½ÅÀåÀÇ ³ëÆó¹° ÇÊÅÍÀÎ »ç±¸Ã¼¿¡ ÈäÅÍ Á¶Á÷ÀÌ »ý±â´Â Èñ±ÍÇÑ ½ÅÀå ÁúȯÀÎ FSGS¸¦ Ä¡·áÇÏ´Â ¾à¹°µµ °³¹ß ÁßÀÔ´Ï´Ù. º¹¿ëÇϰí ÀÖ½À´Ï´Ù.

Á¦¾àÁ¶°Ç

³ôÀº Åõ¼® ¹× ½ÅÀå ÀÌ½Ä ºñ¿ë, FSGS¿¡ ´ëÇÑ ³·Àº ÀÎÁöµµ, Á¦ÇÑµÈ Ä¡·á ¿É¼Ç, ¾ö°ÝÇÑ ±ÔÁ¦ ¹× »óȯ Á¤Ã¥ µîÀÌ ½ÃÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå »ê¾÷ ºÐ¼®

Á¦6Àå Áúȯ À¯Çüº°

Á¦7Àå ¾àÁ¦º°

Á¦8Àå Åõ¿© °æ·Îº°

Á¦9Àå À¯Åë ä³Îº°

Á¦10Àå ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå Áö¿ªº°

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Overview

The global focal segmental glomerulosclerosis drugs market reached US$ 0.7 billion in 2023 and is expected to reach US$ 1.4 billion by 2031, growing at a CAGR of 7.5% during the forecast period 2024-2031.

Focal segmental glomerulosclerosis is a type of renal disorder affecting the small filtering unit of kidneys called glomeruli which involves scarring of the kidney. It is caused by numerous factors such as autoimmune disorders, genetic factors, infection in other parts of the body, and sclerotic diseases.

It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, sickle cell anemia, obstructive sleep apnea, birth, and viruses such as HIV.

Market Dynamics

Drivers

The rising burden of focal segmental glomerulosclerosis drugs(FSGS)

The demand for the global focal segmental glomerulosclerosis drugs market is driven by multiple factors. One of the key factors is the increasing burden of FSGS. Focal segmental glomerulosclerosis drugs(FSGS) is a disease in which scar tissue develops on the glomeruli, the small parts of the kidneys that filter waste from the blood.

FSGS can be caused by a variety of conditions. FSGS is a serious condition that can lead to kidney failure, which can only be treated with dialysis or a kidney transplant.

According to an NCBI research publication in August 2023, focal segmental glomerular sclerosis (FSGS) is a frequently encountered cause of nephrotic syndrome, accounting for 40% of cases in adults and 20% in children.

In addition, a high focus on developing new treatment options is expected to drive the growth of this market over the forecast period. For instance, in February 2023, the drug, called sparsentan, snagged an FDA accelerated approval to treat patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.

Moreover, IgAN, Travere is also developing Filspari for focal segmental glomerulosclerosis drugs(FSGS), an even rarer kidney disease in which scar tissue develops on the kidney's waste filter glomeruli. About 90% of patients diagnosed with IgAN are currently on an ACE inhibitor or an ARB.

Restraints

Factors such as the high cost of dialysis & kidney transplant, limited awareness of FSGS, limited availability of effective treatment options, and stringent regulatory and reimbursement policies, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global focal segmental glomerulosclerosis drugs market is segmented based on disease type, drugs, route of administration, distribution channel, end-user, and region.

The primary focal segmental glomerulosclerosis drugs segment accounted for approximately 45.3% of the global focal segmental glomerulosclerosis drugs market share

The primary focal segmental glomerulosclerosis drugs segment is expected to hold the largest market share over the forecast period. The primary FSGS is usually "idiopathic," referring to the rise of disease without any known, definite, or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults.

Primary FSGS has been associated with the presence of circulating permeability factors/cytokines, which cause foot process effacement and proteinuria. These include corticotrophin-like cytokine factor 1, apoA1b, anti-CD40 Ab, and suPAR. Primary FSGS may respond to corticosteroids, immunomodulatory agents, plasmapheresis, or immunoadsorption3 and is prone to recur post-transplantation.

Moreover, key players' focus on innovative developments would propel this market growth. For instance, in May 2023, CSL Vifor announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis drugs(FSGS) from its partner Travere Therapeutics.

Also, in December 2023, Travere completed a successful pre-NDA meeting for FILSPARI in IgAN. It provides regulatory updates for both IgAN and FSGS.

IgAN is the most common type of primary glomerulonephritis worldwide and a leading cause of kidney failure due to glomerular disease. IgAN is estimated to affect up to 150,000 people in the U.S. and is one of the most common glomerular diseases in Europe and Japan.

Geographical Analysis

North America accounted for approximately 42.1% of the global focal segmental glomerulosclerosis drugs market share

North America region is expected to hold the largest market share over the forecast period. The high prevalence of FSGS in North America is driving the demand for effective FSGS therapeutics. The region has a well-established research and development infrastructure that is constantly driving innovation in FSGS therapeutics. As per Springer's research publication in September 2023, FSGS is predominant in North America, accounting for 19.1% of primary glomerular diseases.

In addition, a major key player's presence, increasing awareness of FSGS among healthcare professionals, and new drug approvals would drive this market growth. For instance, in May 2022, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review.

Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.

Market Segmentation

By Disease Type

By Drugs

By Route of Administration

By Distribution Channel

By End-Users

By Region

Competitive Landscape

The major global players in the focal segmental glomerulosclerosis drugs market include GlaxoSmithKline plc, Pfizer Inc., Travere Therapeutics, Inc., Variant Pharmaceuticals, Inc., Dimerix, Complexa Inc., ChemoCentryx Inc., AstraZeneca, Novartis AG, and Vertex Pharmaceuticals Incorporated among others.

Key Developments

Why Purchase the Report?

The global focal segmental glomerulosclerosis market report would provide approximately 78 tables, 73 figures, and 181 Pages.

Target Audience 2024

Table of Contents

1. Methodology and Scope

2. Definition and Overview

3. Executive Summary

4. Dynamics

5. Industry Analysis

6. By Disease Type

7. By Drugs

8. By Route of Administration

9. By Distribution Channel

10. By End-User

11. By Region

12. Competitive Landscape

13. Company Profiles

LIST NOT EXHAUSTIVE

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â